J9264 HCPCS code: Injection, paclitaxel protein-bound particles, 1 mg
J9264 is the HCPCS Level II code for injection, paclitaxel protein-bound particles, 1 mg. In 2024 Medicare paid an average of $10.62 per service for J9264 across 7,866,261 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 800 per day on DME suppliers. Medicare volume fell 16% from 2022 to 2024 (9,409,425 to 7,866,261 services). In 2024, about 3,243 clinicians billed Medicare for J9264 for 5,054 beneficiaries; Florida, California, Texas accounted for 35% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2006-01-01 |
| Last action effective | 2007-01-01 |
Who bills J9264 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 3,243 |
| Medicare beneficiaries | 5,054 |
| States with claims | 42 |
| Share of services in top 3 states (Florida, California, Texas) | 35% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J9264, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 9,409,425 | 5,895 | $13.50 | $10.77 |
| 2023 | 8,740,919 | 5,416 | $12.22 | $9.74 |
| 2024 | 7,866,261 | 5,054 | $13.33 | $10.62 |
States with the most J9264 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Florida | 998,249 | $10.69 |
| California | 994,494 | $10.67 |
| Texas | 716,066 | $10.62 |
| Illinois | 418,194 | $10.69 |
| New York | 365,495 | $10.63 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| DME suppliers | 800 | Prescribing Information |
| outpatient hospital claims | 800 | Prescribing Information |
| practitioner claims | 800 | Prescribing Information |
Medicare policy articles for this code
- A52450: Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™) (Wellpoint Federal (MAC - Part A, MAC - Part B))
Covered diagnoses (699 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| C00.0 | Malignant neoplasm of external upper lip | 1 |
| C00.1 | Malignant neoplasm of external lower lip | 1 |
| C00.2 | Malignant neoplasm of external lip, unspecified | 1 |
| C00.3 | Malignant neoplasm of upper lip, inner aspect | 1 |
| C00.4 | Malignant neoplasm of lower lip, inner aspect | 1 |
| C00.5 | Malignant neoplasm of lip, unspecified, inner aspect | 1 |
| C00.6 | Malignant neoplasm of commissure of lip, unspecified | 1 |
| C00.8 | Malignant neoplasm of overlapping sites of lip | 1 |
| C00.9 | Malignant neoplasm of lip, unspecified | 1 |
| C01 | Malignant neoplasm of base of tongue | 1 |
Showing 10 of 699. The full list, non-covered diagnoses and CSV export are in Caduvo.
What changed for J9264
- 2006-01-01: J9264 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J9264?
J9264 is the HCPCS Level II code for injection, paclitaxel protein-bound particles, 1 mg. Short descriptor: "Paclitaxel protein bound".
How much does Medicare pay for J9264?
In 2024, the average Medicare payment was $10.62 per service (average allowed $13.33).
Does Medicare cover J9264?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Which diagnoses support coverage for J9264?
Medicare policy articles that cite J9264 list 699 covered ICD-10-CM diagnosis codes across 1 article. The most cited include C00.0 (Malignant neoplasm of external upper lip), C00.1 (Malignant neoplasm of external lower lip), C00.2 (Malignant neoplasm of external lip, unspecified). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of J9264 can be billed per day?
800 on DME suppliers; 800 on outpatient hospital claims; 800 on practitioner claims (NCCI medically unlikely edits).
Related J92 codes
- J9200 — Injection, floxuridine, 500 mg
- J9201 — Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
- J9202 — Goserelin acetate implant, per 3.6 mg
- J9203 — Injection, gemtuzumab ozogamicin, 0.1 mg
- J9204 — Injection, mogamulizumab-kpkc, 1 mg
- J9205 — Injection, irinotecan liposome, 1 mg
- J9206 — Injection, irinotecan, 20 mg
- J9207 — Injection, ixabepilone, 1 mg
- J9208 — Injection, ifosfamide, 1 gram
- J9209 — Injection, mesna, 200 mg
- J9210 — Injection, emapalumab-lzsg, 1 mg
- J9211 — Injection, idarubicin hydrochloride, 5 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J9264
- Watch J9264 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J9264
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.